1051 Audit of Statin Optimisation in Peripheral Arterial Disease and Abdominal Aortic Aneurysmal Disease

Aim High-intensity statins are clinically an effective option for secondary prevention of cardiovascular disease and shown to improve patient outcomes, particularly in patients with peripheral arterial disease (PAD) or abdominal aortic aneurysms (AAA). NICE guidelines state Atorvastatin 80mg as the most cost-effective choice. This guideline provides a clear standard for all patients, which is auditable. Method A prospective study of 314 inpatients under vascular surgery of which 124 were part of the initial data collection. Following an educational intervention, 190 were collected in the second round. Exclusion criteria were applied to both cycles and a total of 52 and 67 patients remained respectively. Those that were switched to Atorvastatin 80mg on discharge were deemed to have been successfully optimised. Results Patients who were suitable for optimisation were compared to those who were discharged on Atorvastatin 80mg showing that 15 out of 52 patients were optimised in the first round and 43 out of 67 patients in the second round. Overall, the percentage optimised increased from 29% to 64% between the two cycles of data collection demonstrating a 2.2-fold increase in the percentage optimised. Conclusions Educational awareness between MDT members has successfully increased statin optimisation amongst PAD and AAA patients. This audit is applicable to most vascular comorbid patients and vital in preventative efforts to reduce the risk of future adverse limb or cardiovascular events, improving overall survival benefit.